カテゴリ： Transparency Market Research, 世界, 医療/バイオ

ウイルスベクター製造の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測

■ 英語タイトル：Viral Vector Production Market (Vector Type: Adenovirus, Adeno-associated Virus, Retroviruses, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23JUL180）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23JUL180
■ 発行日：2023年4月
■ 調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ
■ 産業分野：医療
■ ページ数：256
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ウイルスベクター製造の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の当レポートは、世界のウイルスベクター製造市場規模が、2023年の167億ドルから予測期間中、年平均4.4％で成長し、2031年には173億ドルに達すると予想しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、ベクター種類別（アデノウイルス、アデノ随伴ウイルス、レトロウイルス、その他）分析、疾患別（遺伝病、感染症、がん、その他）分析、用途別（遺伝子治療、ワクチン）分析、モード別（一過性トランスフェクション、安定生産細胞株）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容が含まれています。また、企業情報として、Pfizer, Inc.、Johnson & Johnson、AstraZeneca、Sanofi、Novartis AG、Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)、GlaxoSmithKline plc、Merck KGaA (Merck & Co., Inc.)、Lonza、FUJIFILM Diosynth Biotechnologies, Inc.、Oxford Biomedica plc、Amgen, Inc.、Ferring B.V.、uniQure N.V.、bluebird bio, Inc.、GenScript ProBioなどが含まれています。
・序論
・仮定＆調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界のウイルスベクター製造市場規模：ベクター種類別
- アデノウイルスの市場規模
- アデノ随伴ウイルスの市場規模
- レトロウイルスの市場規模
- その他ベクターの市場規模
・世界のウイルスベクター製造市場規模：疾患別
- 遺伝病における市場規模
- 感染症における市場規模
- がんにおける市場規模
- その他疾患における市場規模
・世界のウイルスベクター製造市場規模：用途別
- 遺伝子治療用ウイルスベクター製造の市場規模
- ワクチン用ウイルスベクター製造の市場規模
・世界のウイルスベクター製造市場規模：モード別
- 一過性トランスフェクションの市場規模
- 安定生産細胞株の市場規模
・世界のウイルスベクター製造市場規模：地域別
- 北米のウイルスベクター製造市場規模
- ヨーロッパのウイルスベクター製造市場規模
- アジア太平洋のウイルスベクター製造市場規模
- 中南米のウイルスベクター製造市場規模
- 中東・アフリカのウイルスベクター製造市場規模
・競争状況

Viral Vector Production Market – Scope of Report
TMR’s report on the global Viral Vector Production Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Viral Vector Production Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Viral Vector Production Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.

The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Viral Vector Production Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Viral Vector Production Market profiled in this report.

Key Questions Answered in Global Viral Vector Production Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Viral Vector Production Market – Research Objectives and Research Approach
The comprehensive report on the global Viral Vector Production Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Viral Vector Production Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Viral Vector Production Market
4. Market Overview
    4.1. Introduction
        4.1.1. Vector Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Viral Vector Production Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Evolution of Gene Therapy
    5.2. Pipeline Analysis
    5.3. Regulatory Scenario, by Region/Globally
    5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Viral Vector Production Market Analysis and Forecast, by Vector Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Vector Type, 2017-2031
        6.3.1. Adenovirus
        6.3.2. Adeno-associated virus
        6.3.3. Retroviruses
        6.3.4. Others (baculoviruses, lentivirus, etc.)
    6.4. Market Attractiveness Analysis, by Vector Type
7. Global Viral Vector Production Market Analysis and Forecast, by Disease
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Disease, 2017-2031
        7.3.1. Genetic Diseases
        7.3.2. Infectious Diseases
        7.3.3. Cancer
        7.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    7.4. Market Attractiveness Analysis, by Disease
8. Global Viral Vector Production Market Analysis and Forecast, by Application
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Application, 2017-2031
        8.3.1. Gene Therapy
        8.3.2. Vaccinology
    8.4. Market Attractiveness Analysis, by Application
9. Global Viral Vector Production Market Analysis and Forecast, by Mode
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by Mode, 2017-2031
        9.3.1. Transient Transfection
        9.3.2. Stable Producer Cell Lines
    9.4. Market Attractiveness Analysis, by Mode
10. Global Viral Vector Production Market Analysis and Forecast, by End-user
    10.1. Introduction & Definition
    10.2. Key Findings / Developments
    10.3. Market Value Forecast, by End-user, 2017-2031
        10.3.1. Pharmaceutical & Biotechnology Companies
        10.3.2. Academic & Research Institutes
        10.3.3. CROs & CDMOs
    10.4. Market Attractiveness Analysis, by End-user
11. Global Viral Vector Production Market Analysis and Forecast, by Region
    11.1. Key Findings
    11.2. Market Value Forecast, by Region
        11.2.1. North America
        11.2.2. Europe
        11.2.3. Asia Pacific
        11.2.4. Latin America
        11.2.5. Middle East & Africa
    11.3. Market Attractiveness Analysis, by Region
12. North America Viral Vector Production Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Vector Type, 2017-2031
        12.2.1. Adenovirus
        12.2.2. Adeno-associated virus
        12.2.3. Retroviruses
        12.2.4. Others (baculoviruses, lentivirus, etc.)
    12.3. Market Value Forecast, by Disease, 2017-2031
        12.3.1. Genetic Diseases
        12.3.2. Infectious Diseases
        12.3.3. Cancer
        12.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    12.4. Market Value Forecast, by Application, 2017-2031
        12.4.1. Gene Therapy
        12.4.2. Vaccinology
    12.5. Market Value Forecast, by Mode, 2017-2031
        12.5.1. Transient Transfection
        12.5.2. Stable Producer Cell Lines
    12.6. Market Value Forecast, by End-user, 2017-2031
        12.6.1. Pharmaceutical & Biotechnology Companies
        12.6.2. Academic & Research Institutes
        12.6.3. CROs & CDMOs
    12.7. Market Value Forecast, by Country, 2017-2031
        12.7.1. U.S.
        12.7.2. Canada
    12.8. Market Attractiveness Analysis
        12.8.1. By Vector Type
        12.8.2. By Disease
        12.8.3. By Application
        12.8.4. By Mode
        12.8.5. By End-user
        12.8.6. By Country
13. Europe Viral Vector Production Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Vector Type, 2017-2031
        13.2.1. Adenovirus
        13.2.2. Adeno-associated virus
        13.2.3. Retroviruses
        13.2.4. Others (baculoviruses, lentivirus, etc.)
    13.3. Market Value Forecast, by Disease, 2017-2031
        13.3.1. Genetic Diseases
        13.3.2. Infectious Diseases
        13.3.3. Cancer
        13.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    13.4. Market Value Forecast, by Application, 2017-2031
        13.4.1. Gene Therapy
        13.4.2. Vaccinology
    13.5. Market Value Forecast, by Mode, 2017-2031
        13.5.1. Transient Transfection
        13.5.2. Stable Producer Cell Lines
    13.6. Market Value Forecast, by End-user, 2017-2031
        13.6.1. Pharmaceutical & Biotechnology Companies
        13.6.2. Academic & Research Institutes
        13.6.3. CROs & CDMOs
    13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.7.1. Germany
        13.7.2. U.K.
        13.7.3. France
        13.7.4. Spain
        13.7.5. Italy
        13.7.6. Rest of Europe
    13.8. Market Attractiveness Analysis
        13.8.1. By Vector Type
        13.8.2. By Disease
        13.8.3. By Application
        13.8.4. By Mode
        13.8.5. By End-user
        13.8.6. By Country/Sub-region
14. Asia Pacific Viral Vector Production Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Vector Type, 2017-2031
        14.2.1. Adenovirus
        14.2.2. Adeno-associated virus
        14.2.3. Retroviruses
        14.2.4. Others (baculoviruses, lentivirus, etc.)
    14.3. Market Value Forecast, by Diseases, 2017-2031
        14.3.1. Genetic Diseases
        14.3.2. Infectious Diseases
        14.3.3. Cancer
        14.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    14.4. Market Value Forecast, by Application, 2017-2031
        14.4.1. Gene Therapy
        14.4.2. Vaccinology
    14.5. Market Value Forecast, by Mode, 2017-2031
        14.5.1. Transient Transfection
        14.5.2. Stable Producer Cell Lines
    14.6. Market Value Forecast, by End-user, 2017-2031
        14.6.1. Pharmaceutical & Biotechnology Companies
        14.6.2. Academic & Research Institutes
        14.6.3. CROs & CDMOs
    14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.7.1. China
        14.7.2. Japan
        14.7.3. India
        14.7.4. Australia & New Zealand
        14.7.5. Rest of Asia Pacific
    14.8. Market Attractiveness Analysis
        14.8.1. By Vector Type
        14.8.2. By Disease
        14.8.3. By Application
        14.8.4. By Mode
        14.8.5. By End-user
        14.8.6. By Country/Sub-region
15. Latin America Viral Vector Production Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Vector Type, 2017-2031
        15.2.1. Adenovirus
        15.2.2. Adeno-associated virus
        15.2.3. Retroviruses
        15.2.4. Others (baculoviruses, lentivirus, etc.)
    15.3. Market Value Forecast, by Disease, 2017-2031
        15.3.1. Genetic Diseases
        15.3.2. Infectious Diseases
        15.3.3. Cancer
        15.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    15.4. Market Value Forecast, by Application, 2017-2031
        15.4.1. Gene Therapy
        15.4.2. Vaccinology
    15.5. Market Value Forecast, by Mode, 2017-2031
        15.5.1. Transient Transfection
        15.5.2. Stable Producer Cell Lines
    15.6. Market Value Forecast, by End-user, 2017-2031
        15.6.1. Pharmaceutical & Biotechnology Companies
        15.6.2. Academic & Research Institutes
        15.6.3. CROs & CDMOs
    15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.7.1. Brazil
        15.7.2. Mexico
        15.7.3. Rest of Latin America
    15.8. Market Attractiveness Analysis
        15.8.1. By Vector Type
        15.8.2. By Disease
        15.8.3. By Application
        15.8.4. By Mode
        15.8.5. By End-user
        15.8.6. By Country/Sub-region
16. Middle East & Africa Viral Vector Production Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast, by Vector Type, 2017-2031
        16.2.1. Adenovirus
        16.2.2. Adeno-associated virus
        16.2.3. Retroviruses
        16.2.4. Others (baculoviruses, lentivirus, etc.)
    16.3. Market Value Forecast, by Disease, 2017-2031
        16.3.1. Genetic Diseases
        16.3.2. Infectious Diseases
        16.3.3. Cancer
        16.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    16.4. Market Value Forecast, by Application, 2017-2031
        16.4.1. Gene Therapy
        16.4.2. Vaccinology
    16.5. Market Value Forecast, by Mode, 2017-2031
        16.5.1. Transient Transfection
        16.5.2. Stable Producer Cell Lines
    16.6. Market Value Forecast, by End-user, 2017-2031
        16.6.1. Pharmaceutical & Biotechnology Companies
        16.6.2. Academic & Research Institutes
        16.6.3. CROs & CDMOs
    16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        16.7.1. GCC Countries
        16.7.2. South Africa
        16.7.3. Rest of Middle East & Africa
    16.8. Market Attractiveness Analysis
        16.8.1. By Vector Type
        16.8.2. By Disease
        16.8.3. By Application
        16.8.4. By Mode
        16.8.5. By End-user
        16.8.6. By Country/Sub-region
17. Competition Landscape
    17.1. Market Player – Competition Matrix (By Tier and Size of companies)
    17.2. Market Share Analysis By Company (2021)
    17.3. Company Profiles
        17.3.1. Pfizer, Inc.
            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.1.2. Test Type Portfolio
            17.3.1.3. Financial Overview
            17.3.1.4. SWOT Analysis
            17.3.1.5. Strategic Overview
        17.3.2. Johnson & Johnson
            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.2.2. Test Type Portfolio
            17.3.2.3. Financial Overview
            17.3.2.4. SWOT Analysis
            17.3.2.5. Strategic Overview
        17.3.3. AstraZeneca
            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.3.2. Test Type Portfolio
            17.3.3.3. Financial Overview
            17.3.3.4. SWOT Analysis
            17.3.3.5. Strategic Overview
        17.3.4. Sanofi
            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.4.2. Test Type Portfolio
            17.3.4.3. Financial Overview
            17.3.4.4. SWOT Analysis
            17.3.4.5. Strategic Overview
        17.3.5. Novartis AG
            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.5.2. Test Type Portfolio
            17.3.5.3. Financial Overview
            17.3.5.4. SWOT Analysis
            17.3.5.5. Strategic Overview
        17.3.6. Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)
            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.6.2. Test Type Portfolio
            17.3.6.3. Financial Overview
            17.3.6.4. SWOT Analysis
            17.3.6.5. Strategic Overview
        17.3.7. GlaxoSmithKline plc
            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.7.2. Test Type Portfolio
            17.3.7.3. Financial Overview
            17.3.7.4. SWOT Analysis
            17.3.7.5. Strategic Overview
        17.3.8. Merck KGaA (Merck & Co., Inc.)
            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.8.2. Test Type Portfolio
            17.3.8.3. Financial Overview
            17.3.8.4. SWOT Analysis
            17.3.8.5. Strategic Overview
        17.3.9. Lonza
            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.9.2. Test Type Portfolio
            17.3.9.3. Financial Overview
            17.3.9.4. SWOT Analysis
            17.3.9.5. Strategic Overview
        17.3.10. FUJIFILM Diosynth Biotechnologies Inc.
            17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.10.2. Test Type Portfolio
            17.3.10.3. Financial Overview
            17.3.10.4. SWOT Analysis
            17.3.10.5. Strategic Overview
        17.3.11. Oxford Biomedica plc
            17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.11.2. Test Type Portfolio
            17.3.11.3. Financial Overview
            17.3.11.4. SWOT Analysis
            17.3.11.5. Strategic Overview
        17.3.12. Amgen Inc.
            17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.12.2. Test Type Portfolio
            17.3.12.3. Financial Overview
            17.3.12.4. SWOT Analysis
            17.3.12.5. Strategic Overview
        17.3.13. Ferring B.V.
            17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.13.2. Test Type Portfolio
            17.3.13.3. Financial Overview
            17.3.13.4. SWOT Analysis
            17.3.13.5. Strategic Overview
        17.3.14. uniQure N.V.
            17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.14.2. Test Type Portfolio
            17.3.14.3. Financial Overview
            17.3.14.4. SWOT Analysis
            17.3.14.5. Strategic Overview
        17.3.15. bluebird bio, Inc.
            17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.15.2. Test Type Portfolio
            17.3.15.3. Financial Overview
            17.3.15.4. SWOT Analysis
            17.3.15.5. Strategic Overview
        17.3.16. GenScript ProBio
            17.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.16.2. Test Type Portfolio
            17.3.16.3. Financial Overview
            17.3.16.4. SWOT Analysis
            17.3.16.5. Strategic Overview
        17.3.17. Thermo Fisher Scientific, Inc.
            17.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.17.2. Test Type Portfolio
            17.3.17.3. Financial Overview
            17.3.17.4. SWOT Analysis
            17.3.17.5. Strategic Overview
        17.3.18. Gamaleya Research Institute
            17.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.18.2. Test Type Portfolio
            17.3.18.3. Financial Overview
            17.3.18.4. SWOT Analysis
            17.3.18.5. Strategic Overview

List of Tables

Table 01: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 02: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 03: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 04: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 05: Global Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 06: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Region, 2017-2032

Table 07: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Country, 2017-2032

Table 08: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 09: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 10: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 11: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 12: North America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 13: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 14: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 15: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 16: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 17: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 18: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 19: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 20: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 21: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 22: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 23: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 24: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 25: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 26: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 27: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 28: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 29: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 30: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 31: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 32: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 33: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 34: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 35: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 36: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • C反応性タンパク質検査の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • 間葉系幹細胞の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • 遺伝子検査サービスの世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • エクソソーム技術の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • 塞栓保護機器の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23JUL180 )"ウイルスベクター製造の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測" (英文：Viral Vector Production Market (Vector Type: Adenovirus, Adeno-associated Virus, Retroviruses, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。